Research programme: attention deficit hyperactivity disorder therapeutics - Ensysce Biosciences

Drug Profile

Research programme: attention deficit hyperactivity disorder therapeutics - Ensysce Biosciences

Alternative Names: Abuse-resistant amphetamine; Amfetamine - PharmacoFore; Dexamfetamine - Ensysce Biosciences; Dexamphetamine - Ensysce Biosciences; PF-08; PFR 08001; PFR 8026

Latest Information Update: 24 Feb 2016

Price : $50

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 24 Feb 2016 Preclinical trials in Attention-deficit hyperactivity disorder in USA (PO, Immediate-release) before February 2016
  • 24 Feb 2016 Preclinical trials in Attention-deficit hyperactivity disorder in USA (PO, Controlled-release) before February 2016
  • 19 Jan 2016 Signature Therapeutics has merged into Ensysce Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top